Organization & Developments: Codagenix

Parents

2020: Codagenix, Serum Institute take nasal COVID-19 vaccine into clinic
2023: Nasal Vax for COVID-19 Has Encouraging Early Clinical Results as U.S. Pumps $18.5M in Nasal Vaccine Research
Codagenix Inc. spun out of the laboratory of National Academy of Science Member Eckard Wimmer at Stony Brook University in 2012.
Codagenix is located at the Broad Hollow Bioscience Research Park in Long Island, NY. Our programs are supported by Adjuvant Capital, Euclidean Capital, TopSpin Partners, and government agencies such as the USDA, NIH/NIAID, and
Inspired by the promise the technology holds, Codagenix was founded by our CSO Steffen Mueller, PhD, our CEO J. Robert Coleman, PhD, MBA and Distinguished Professor Eckard Wimmer to commercialize this viral design technology to answer the unmet need for more effective vaccines and increased treatment options for cancer.
Software-driven approach to vaccine design
The ability to synthesize viruses opens the door to rationally redesigning viral genomes to turn viruses into effective prophylactic vaccines or oncolytic therapies (Coleman et al. Science 2008).
this discovery serves as the core concept of Codagenix (Cello et al. Science 2002).